Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa

Olgac A., İNCİ A., OKUR İ., BİBEROĞLU G., Oguz D., EZGÜ F. S., ...Daha Fazla

ANNALS OF NUTRITION AND METABOLISM, cilt.76, sa.4, ss.233-241, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 76 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1159/000509335
  • Dergi Adı: ANNALS OF NUTRITION AND METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.233-241
  • Anahtar Kelimeler: Glycogen storage disease type IIIIa, Cori-Forbes disease, Modified Atkins diet, Ketogenic diet, Hypertrophic cardiomyopathy, CHILDREN, CARDIOMYOPATHY, RECOMMENDATIONS, ADOLESCENTS, MANAGEMENT
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction: Glycogen storage disease Type III (GSD III) is an autosomal recessive disease caused by the deficiency of glycogen debranching enzyme, encoded by the AGL gene. Two clinical types of the disease are most prevalent: GSD IIIa involves the liver and muscle, whereas IIIb affects only the liver. The classical dietetic management of GSD IIIa involves prevention of fasting, frequent feeds with high complex carbohydrates in small children, and a low-carb-high-protein diet in older children and adults. Recently, diets containing high amount of fat, including ketogenic and modified Atkins diet (MAD), have been suggested to have favorable outcome in GSD IIIa. Methods: Six patients, aged 3-31 years, with GSD IIIa received MAD for a duration of 3-7 months. Serum glucose, transaminases, creatine kinase (CK) levels, capillary ketone levels, and cardiac parameters were followed-up. Results: In all patients, transaminase levels dropped in response to MAD. Decrease in CK levels were detected in 5 out of 6 patients. Hypoglycemia was evident in 2 patients but was resolved by adding uncooked cornstarch to diet. Conclusion: Our study demonstrates that GSD IIIa may benefit from MAD both clinically and biochemically.